Article

A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder.

Department of Psychiatry, Massachusetts General Hospital, Boston, USA.
The Journal of Clinical Psychiatry (Impact Factor: 5.14). 10/2000; 61(9):638-42. DOI: 10.4088/JCP.v61n0907
Source: PubMed

ABSTRACT Our purpose was to evaluate the overall efficacy and tolerability of novel antipsychotic medications for patients with bipolar disorder type I.
A retrospective study of the Massachusetts General Hospital Bipolar Clinic database was carried out to identify 50 consecutive treatment trials in patients with DSM-IV bipolar disorder type I who had received adjunctive treatment with risperidone, olanzapine, or clozapine, along with standard mood stabilizers. The treatment charts of those patients (N = 42) were reviewed for details of adverse effects, tolerability, and efficacy of medication.
Overall results indicated equivalent efficacy in novel antipsychotic treatments according to change in Clinical Global Impressions scale score. Levels of extrapyramidal symptoms were similar in all groups and occurred in 12/42 patients (28.6%). Prolactin-related side effects were not observed in any patients. There were no cases of affective switch or worsening of mania. Substantial weight gain of more than 10 lb (4.5 kg) was significantly greater in patients treated with olanzapine.
These results suggest that the efficacy and tolerability of risperidone, olanzapine, and clozapine are similar in patients with bipolar disorder. One major differentiation factor of these drugs appears to be weight gain, particularly between olanzapine and risperidone. This may, in part, also be related to the need to use mood-stabilizing agents, like lithium or divalproex sodium, which may potentiate the weight-gain effect of novel antipsychotics.

0 Bookmarks
 · 
151 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Antipsychotics (AP) induce weight gain. However, reviews and meta-analyses generally are restricted to second generation antipsychotics (SGA) and do not stratify for duration of AP use. It is hypothesised that patients gain more weight if duration of AP use is longer. A meta-analysis was conducted of clinical trials of AP that reported weight change. Outcome measures were body weight change, change in BMI and clinically relevant weight change (7% weight gain or loss). Duration of AP-use was stratified as follows: ≤6 weeks, 6-16 weeks, 16-38 weeks and >38 weeks. Forest plots stratified by AP as well as by duration of use were generated and results were summarised in figures. 307 articles met inclusion criteria. The majority were AP switch studies. Almost all AP showed a degree of weight gain after prolonged use, except for amisulpride, aripiprazole and ziprasidone, for which prolonged exposure resulted in negligible weight change. The level of weight gain per AP varied from discrete to severe. Contrary to expectations, switch of AP did not result in weight loss for amisulpride, aripiprazole or ziprasidone. In AP-naive patients, weight gain was much more pronounced for all AP. Given prolonged exposure, virtually all AP are associated with weight gain. The rational of switching AP to achieve weight reduction may be overrated. In AP-naive patients, weight gain is more pronounced.
    PLoS ONE 04/2014; 9(4):e94112. · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This report will describe clinical experience using risperidone in substance-dependent patients with bipolar disorder. Method. Thirty-six male patients with SUD and bipolar disorder (DSMIII-R), who were admitted to a voluntary, post-detoxification, intermediatecare inpatient substance abuse program, were assessed weekly using the Clinical Global Impressions scale to assess overall functioning. All patients were treated with risperidone (mean dose 2.3 mg/day) in an open-label, naturalistic trial. 20 Results. Of the 36 patients, 11 dropped out before a follow-up appointment. Twenty patients (56%) reported improved or much improved on the CGI scale, and 5 (%) were rated unchanged. Conclusion. The results of this observational trial suggest that risperidone is moderately effective and well tolerated in bipolar patients with substance use disorders and comorbid psychiatric illnesses. In the short-term, risperidone treatment may also contribute to the likelihood of completing substance abuse treatment.
    Journal of Dual Diagnosis 06/2008; 4(2):186-196. · 0.80 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Estudos recentes têm demonstrado que a eficácia do lítio é significativamente inferior à descrita pelos primeiros trabalhos, embora ainda seja a medicação de referência no tratamento do transtorno afetivo bipolar. Apesar de um perfil de segurança desfavorável, os antipsicóticos clássicos sempre apresentaram um papel importante no tratamento desse transtorno psiquiátrico, especialmente como coadjuvante em sua fase maníaca aguda. Os autores, utilizando informação obtida no Medline, fizeram uma revisão acerca do papel dos antipsicóticos atípicos no tratamento dos pacientes bipolares. Baseado nos dados da literatura, a olanzapina mostrou-se bastante eficaz no manejo da mania aguda, quando uma média de 63,5% dos pacientes apresentaram melhora significativa em estudos duplo-cego controlados, apresentando ganho de peso como único efeito colateral relevante. A clozapina e, mais ainda, a risperidona apresentaram dados menos consistentes, grande parte em função de deficiências metodológicas dos poucos estudos conduzidos até o presente estudo. Os dados prelimi- nares relativos à eficácia desse grupo farmacológico nos quadros refratários e nos sintomas depressivos são promissores, mas ainda não definitivos. Em relação a seus efeitos potenciais como estabilizadores do humor, não existem evidências conclusivas oriundas de estudos controlados, mas há interesse considerável para reali- zação de investigações em pacientes bipolares tratados com antipsicóticos atípicos por períodos de tempo mais prolongados. Pesquisas futuras poderão tornar mais claras essas possíveis características terapêuticas. Transtorno bipolar. Planejamento de assistência ao paciente. Agentes antipsicóticos. Neurolépticos. Revisão. Even though lithium is still the choice drug in the treatment of bipolar disorder, recent studies have shown that it has a significant lower efficacy than previously described in earlier studies. Despite its adverse side effects, typical antipsychotic agents have often had a prominent role in the treatment of this psychiatric disorder, espe- cially in the acute manic phase. Recently new alternatives have become available with the development of newer atypical antipsychotic agents. A comprehensive Medline search was conducted, and all available literature con- cerning the role of atypical antipsychotics in the treatment of bipolar patients was retrieved. Olanzapine showed to be quite effective in the treatment of acute mania, and it was found that an average of 63.5% of the patients had a significant improvement in double blind controlled studies, with weight gain as the major side effect. Data was less robust for clozapine and risperidone, mainly due to methodological limitations of the few available studies. It was also found a considerable interest in future investigating the efficacy of these pharmacological agents in refractory cases and in the treatment of the disorder's depressive phase. Additionally, there has been extensive interest in evaluating their potential action as mood stabilizers, for which there will be a need of longer-term longitudinal studies. Bipolar disorder. Patient care planning. Antipsychotic agents. Neuroleptics. Review.
    Revista Brasileira de Psiquiatria 03/2002; 24(1):34-43. · 1.64 Impact Factor

Preview

Download
5 Downloads
Available from